nRichDX

nRichDX is a biotechnology startup based in Irvine, CA, founded in 2018, focusing on revolutionizing the liquid biopsy sample preparation process. The company's slogan emphasizes its goal of delivering greater yields for higher sensitivity in liquid biopsy tests, particularly for early cancer detection. nRichDX has developed a unique sample prep platform that significantly enhances analyte yields, including cfDNA, ctDNA, cfTNA, and cfRNA, addressing a critical need in the multi-billion-dollar liquid biopsy and precision medicine markets. The company's technology, which began development in 2016 and was introduced in late 2018, has received a 510K-exempt status, positioning it as a highly differentiated and universal sample prep system. This tech addresses a pervasive issue in precision medicine by mitigating inaccurate diagnostic results (up to 50%) in liquid biopsy-based molecular tests, such as NGS, PCR, and Micro Array, due to a lack of target material. nRichDX's innovative platform not only improves workflow and test sensitivity but also ensures consistently reliable results, thereby potentially increasing revenue and reducing operational costs and complexity. The startup operates in the biotechnology, health care, and medical devices industries, positioning itself at the intersection of groundbreaking technological innovation and critical healthcare solutions. As of the latest available information, nRichDX's last investment details and investors remain undisclosed.